Q2 FY2026 EarningsQ2 FY26 beat consensus across all major metrics: revenue $1,368M vs. $1,313M expected, and adjusted EPS $0.34 vs. $0.27. Performance was driven by an 11% organic growth in U.S. Pet Health, fueled by blockbuster innovation from Zenrelia and Credelio Quattro. Adjusted gross margin of 58.1% exceeded the 56.7% mean estimate, while FY26 full-year revenue and adjusted EBITDA guidance were both raised above previous consensus, signaling accelerating momentum in the innovation portfolio.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Elanco Animal Health(ELAN) the Revenue is 1.368 B (+10.23%), Beat estimate;the EBIT is 265 M (+17.26%), Beat estimate;the EPS is 0.11 (+450%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
1.37B10.23%
1.31B5.83%
+0.05B4.40%
EBITExceed expectations
0.27B17.26%
0.22B1.96%
+0.04B19.22%
EPSExceed expectations
0.11450.00%
0.013333.35%
+0.0967483.35%
Upcoming earnings report - Q3 FY2026
Available dateNov 6, 2026
Estimate Revenue$1.206 B
Estimate EBIT$178.27 M
Estimate EPS-$0.0233
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf